Phagocytic cells, including normal human blood neutrophils and monocytes, metabolize 25-hydroxyvitamin D3 in vitro to more polar metabolites. Cells of the human monoblastic cell line U937 produced three metabolites when incubated with 25-hydroxyvitamin D3. One of these metabolites, previously designated peak m, has its maximal absorbance at 310 nm. Mass spectral analysis of the trimethylsilylated derivatives of peak mI revealed a spectral pattern very similar to that published for the trimethylsilylated derivatives of 19-nor-10-keto-25-hydroxyvitamin D3. The biosynthetic 19-nor-10-keto-25-hydroxyvitamin D3 was active in the induction of differentiation of U937 cells. Nuclear) as described (1). Incubation was terminated by the addition of an equal volume of methylene chloride/methanol (2:1, vol/vol) to the medium. An organic extraction of the cells and medium was performed followed by a preparative chromatography as described (1). The extract was purified by three consecutive HPLC steps as described (1). The solvent systems included methylene chloride/methanol (95:5, vol/vol); hexane/1-propanol (9:1, vol/vol) and methylene chloride/methanol (98:2, vol/vol). The chromatographic systems employed a Zorbax-Sil column (0.65 x 25 cm, microsilica, DuPont) and a solvent flow rate of 0.5-1.0 ml/min. The eluate fractions containing peak III were stored at -20°C under argon gas in 95% ethanol between the chromatographic steps. Prior to mass spectroscopy, the ultraviolet absorbance spectrum of the peak III fraction was F-12 (1:1, vol/vol) containing 5% fetal bovine serum, penicillin (0.1 unit/ml), and streptomycin sulfate (100 ,ug/ml). la,25-(OH)2D3 or peak III (10 nM, based on UV absorbance) was added to the medium, in 10 ,ul of95% ethanol. A lymphokine-rich conditioned medium (interleukin 2 preparation, Meloy Laboratories, Springfield, VA) was added to the medium to 10% (vol/vol). The counting of adherent and nonadherent cells was as described (7).
of differentiation of U937 cells.
Phagocytic cells metabolize 25-hydroxyvitamin D3 [25-(OH)D3
] in vitro to several metabolites. This metabolism of 25-(OH)D3 has been observed with human blood neutrophils and monocytes (1) , rodent peritoneal macrophages (2), human pulmonary alveolar macrophages (3, 4) and transformed cells of hematopoietic origin (5, 6) . In our laboratory all of these phagocytes have consistently metabolized 25-(OH)D3 to three metabolites, one of which comigrated with authentic la,25-dihydroxyvitamin D3 [la,25-(OH)2D3] in some highperformance liquid chromatography systems and was designated peak III (1). Here we report the identification of peak III as 19-nor-10-keto-25-(OH)D3 by ultraviolet absorbance and mass spectrometry. Preliminary evidence for a biological activity of 19-nor-10-keto-25-(OH)D3 is presented.
METHODS
U937 Cells. Metabolism of 25-(OH)D3. U937 is a monoblastic cell line of human origin. U937 cells were incubated with either 25-(OH)D3 or 25-(OH)[26,27-3H]D3 (New England Nuclear) as described (1) . Incubation was terminated by the addition of an equal volume of methylene chloride/methanol (2:1, vol/vol) to the medium. An organic extraction of the cells and medium was performed followed by a preparative chromatography as described (1) . The extract was purified by three consecutive HPLC steps as described (1) . The solvent systems included methylene chloride/methanol (95:5, vol/vol); hexane/1-propanol (9:1, vol/vol) and methylene chloride/methanol (98:2, vol/vol). The chromatographic systems employed a Zorbax-Sil column (0.65 x 25 cm, microsilica, DuPont) and a solvent flow rate of 0.5-1.0 ml/min. The eluate fractions containing peak III were stored at -20°C under argon gas in 95% ethanol between the chromatographic steps. Prior to mass spectroscopy, the ultraviolet absorbance spectrum of the peak III fraction was The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
tific, was employed. After injection of 1 ;lI of sample at ambient temperature, the injection zone of the column was inserted into the GC oven, which was held at 1500C. The oven then was heated as rapidly as possible to 2500C and then programmed at 6 degrees/min to 3200(. The mass spectrometer was operated in the electron-impact mode (70-eV electron energy, 100-A trap current, 4-kV accelerating voltage) and scanned at a rate of 0.7 sec/decade from m/z 800 to 100 with a scan cycle time of 1 
RESULTS
The U937 cells converted the substrate, 25-(OH)D3, to a substance previously designated as peak III to distinguish it from la,25-(OH)2D3, which was coeluted with peak III in early work on this project (1, 2) . When the substrate concentration was 1 ;LM and the incubation period was 3 hr, a quantity of peak III sufficient for measurement of the ultraviolet absorbance was produced. Fig. 1 Fig. 2A shows the total-ion-current chromatogram of the derivatized peak-III material from the cell extract. Two unique peaks, 1 and 2, were identified. The retention times of these two peaks were 345 sec and 387 sec, respectively. The mass spectra from these two peaks correspond to the bis(trimethylsilyl) ether derivative of 19-nor-10-keto-25-(OH)D3 (Fig. 2C ) and the tris(trimethylsilyl) derivative of its thermal rearrangement product (Fig. 2B ). Fig. 2D shows the mass spectrum of the trimethylsilyl ether derivative of authentic 19-nor-10-keto-25-(OH)D3. The major product detected by GC/MS shows the pattern that corresponds to the rearrangement product. The mass spectral pattern depicted in Fig. 2C is nearly identical to that published by Lester et al. Derivatization of the human cell extracts with (Me3 Si)2TFA alone gave variable results; when (Me3Si)2TFA and dry pyridine were used together, the main product was a different compound, also of molecular weight 546, with a retention time of 321 sec and for which the major fragment ions were at m/z 528 and 513. There was no M+ -43 ion. In addition, peak 1 and a small peak 2 ( Fig. 2A) were observed. When this material was subjected to further derivatization with (Me3Si)2TFA plus (Me3Si)Im, GC peak 1 became the major product.
Previous work in this laboratory showed that la,25-(OH)2D3 inhibited the growth of U937 cells while inducing their differentiation (10) . Biosynthetic 19-nor-10-keto-25-(OH)D3 (peak III) was tested for its ability to alter the growth and differentiation of U937 cells (Table 1) Proc. Natl. Acad. Sci. USA 82 (1985) cells while increasing the number of adherent cells (7) . The addition of 19-nor-10-keto-25-(OH)D3 to lymphokine-enriched medium increased the total number of adherent cells and raised the percentage of adherent cells to -2.5 times the value associated with lymphokines alone (Table 1) . For comparison, the addition of la,25-(OH)2D3 to the lymphokine-enriched medium increased the total number of adherent cells and raised the percentage of adherent cells to >4 times the value associated with the lymphokines alone ( Table 1 ). All three conditions markedly inhibited the proliferation of the U937 cells. The growth inhibition was due predominantly to the presence of the lymphokines (Table 1) .
DISCUSSION
A metabolite of 25-(OH)D3 produced in vitro by phagocytic cells is now identified by ultraviolet absorbance and mass spectrometry as 19-nor-10-keto-25-(OH)D3. This metabolite, previously designated as peak III, was formed when 25-(OH)D3 was incubated with phagocytic cells (1) . Usually <1% of the total substrate was converted to this product. Unless high substrate concentrations are employed, the amount of peak III formed was not sufficient for structural identification. For the work described here, we employed a substrate concentration of 1 gM and an incubation period of 3 hr. The cells and medium were extracted with organic solvents and the extracts were serially chromatographed on three different HPLC systems. A fraction corresponding to peak III had an ultraviolet-absorbance maximum at 310 nm, which is characteristic of the 10-keto-5,7-diene chromophore of 19-nor-10-keto vitamin D derivatives (9) . After derivatization of the peak-Ill fraction with (Me3Si)2TFA plus (Me3Si)Im, GC/MS analysis revealed the presence of two compounds derived from 25-(OH)D3, as indicated by the production of a fragment with m/z 131. One of the compounds gave a molecular ion at m/z 546 and the other, a molecular ion at m/z 618 (Fig. 2) . The Mr 546 component revealed a fragmentation pattern that was nearly identical to the published electron-impact mass spectrum of the trimethylsilylated derivative of 19-nor-10-keto-25-(OH)D3 (8) . The second component (Mr 618) emerged from the GC column before the bis(trimethylsilyl) ether and was consistent with a tris(trimethylsilyl) derivative of the same compound. The same molecular ion (m/z 618) and fragmentation pattern were produced when authentic 19-nor-10-keto-25-(OH)D3 was derivatized under identical conditions (Fig. 2 B  and D) . Assuming that the structural integrity of the target compound (Fig. 3, structure I ) is preserved, this by-product would likely be an enol-ether derivative of the 19-nor-10-keto-25-(OH)D3 (Fig. 3, structure M) . However, when the "peak-Ill" material from U937 cells was treated with (Me3Si)2TFA and pyridine at 900, a different product of Mr 546 was formed in addition to lesser quantities of the compounds in GC peaks 1 and 2 (Fig. 2) . Because there was no M+ -43 peak in the mass spectrum, we ascribe to it structure IV (Fig. 3) , which can be formed from I by base-catalyzed cyclization. Further derivatization with (Me3Si)Im and (Me3Si)2TFA resulted in the loss ofIV in favor of the Mr 618 component. This product would be expected to have the structure V (Fig. 3) . Since only one component ofMr 618 is formed under the various silylation conditions employed, it is likely that intramolecular rearrangement of II occurs to produce V via IV when (Me3Si)2TFA and (Me3Si)Im are employed (Fig. 3) and that compound m is not produced. Lack of authentic 19-nor-10-keto-25-(OH)D3 prevented further studies of derivatization methods that might produce a single species.
19-Nor-10-keto-25-(OH)D3 was originally recovered from incubations of cow rumen with 25-(OH)D3 (9) . Its formation was apparently due to the microorganisms in the rumen, since sterilized rumen did not metabolize 25-(OH)D3 (9) . It has subsequently been reported that cultured dog kidney cells (8) and HL-60 cells (5, 6 ) metabolize 25-(OH)D3 to this metabolite. 19-nor-10-keto-25-(OH)D3 had been initially regarded as a step in a degradation pathway because it had little or no biological activity (9) . It had a much weaker effect on the intestinal absorption of calcium than did vitamin D and it had no measurable effect on bone calcium mobilization (9). Calcium mobilization was observed when the 19-nor-10-keto derivative was added to a more sensitive, fetal calvarial preparation (11) . In our laboratory, 19-nor-10-keto-25-(OH)D3 was capable of inducing U937 adhesion and inhibiting cellular proliferation (Table 1) . Dose-response studies of this action on U937 cells have not been performed because there is presently no supply of this metabolite other than the material synthesized by the phagocytic cells. In lymphokineenriched medium, la,25-(OH)2D3 produced effects on growth and differentiation of U937 cells that were greater than the effects produced by the HPLC fraction containing 19-nor-10-keto-25-(OH)D3. The difference in the observed bioactivity of the two metabolites may be due partly to the use of biosynthetic 19-nor-10-keto-25-(OH)D3 in contrast to the highly purified, crystalline 1a,25-(OH)2D3.
Phagocytic cells from several species, whether freshly isolated or maintained in culture for several days, produced the compound previously designated peak III, now shown to be 19-nor-10-keto-25-(OH)D3, from 25-(OH)D3 (1, 2) . This metabolite is similar to la,25-(OH)2D3 in its ability to synergistically enhance the lymphokine-induced differentiation of a monocytic model, the U937 cell line (10) . These findings suggest the presence of a paracrine or autocrine process. Phagocytic cells metabolize 25-(OH)D3 to 19-nor-10-keto-25-(OH)D3, which is capable of enhancing their differentiation. This process may occur in vivo as a part of the growth and differentiation of phagocytes.
